Possible Dark Matter Annihilation Signal in the AMS-02 Antiproton Data.

Phys Rev Lett

Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210008, People's Republic of China.

Published: May 2017

Using the latest AMS-02 cosmic-ray antiproton flux data, we search for a potential dark matter annihilation signal. The background parameters about the propagation, source injection, and solar modulation are not assumed a priori but based on the results inferred from the recent B/C ratio and proton data measurements instead. The possible dark matter signal is incorporated into the model self-consistently under a Bayesian framework. Compared with the astrophysical background-only hypothesis, we find that a dark matter signal is favored. The rest mass of the dark matter particles is ∼20-80  GeV, and the velocity-averaged hadronic annihilation cross section is about (0.2-5)×10^{-26}  cm^{3} s^{-1}, in agreement with that needed to account for the Galactic center GeV excess and/or the weak GeV emission from dwarf spheroidal galaxies Reticulum 2 and Tucana III. Tight constraints on the dark matter annihilation models are also set in a wide mass region.

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevLett.118.191101DOI Listing

Publication Analysis

Top Keywords

dark matter
24
matter annihilation
12
annihilation signal
8
matter signal
8
dark
6
matter
5
annihilation
4
signal
4
signal ams-02
4
ams-02 antiproton
4

Similar Publications

Background: The 18F-AV-1451 radioligand enables in-vivo identification of tau neurofibrillary tangles that are considered as biomarkers of neurodegeneration in Alzheimer Disease (AD). However, off-target radioligand binding is also observed in basal ganglia, known as an iron-rich region. Hence, it is important to distinguish between radioligand-identified tissue neurodegeneration and iron-related radioligand binding effects.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.

Background: AD is defined by cortical amyloid-β (Aβ), tau neurofibrillary tangles, and neurodegeneration, pathological processes which may contribute to cognitive decline by altering large scale functional brain networks. To test this hypothesis, we examined whether plasma biomarkers of AD pathology (Aβ, phosphorylated tau [pTau-181]), astrogliosis (glial fibrillary acidic protein [GFAP]), and neuronal injury (neurofilament light chain [NfL]) related to longitudinal changes in resting-state functional connectivity (rsFC) in cognitively unimpaired participants from the Baltimore Longitudinal Study of Aging.

Method: Baseline plasma biomarkers were measured with Quanterix SIMOA assays.

View Article and Find Full Text PDF

Background: Robust methods are needed for preclinical evaluation of novel Alzheimer Disease (AD) therapies to accelerate drug discovery. Quantitative Gradient Recalled Echo (qGRE) MRI shows significant promise to provide insight into neurodegeneration in AD prior to atrophy development in humans, with qGRE R2t* metric (tissue-specific subcomponent of R2*) highlighting areas of low neuronal density (doi:10.3233/JAD-210503).

View Article and Find Full Text PDF

Background: Robust methods are needed for preclinical evaluation of novel Alzheimer Disease (AD) therapies to accelerate drug discovery. Quantitative Gradient Recalled Echo (qGRE) MRI shows significant promise to provide insight into neurodegeneration in AD prior to atrophy development in humans, with qGRE R2t* metric (tissue-specific subcomponent of R2*) highlighting areas of low neuronal density (doi:10.3233/JAD-210503).

View Article and Find Full Text PDF

Background: The 18F-AV-1451 radioligand enables in-vivo identification of tau neurofibrillary tangles that are considered as biomarkers of neurodegeneration in Alzheimer Disease (AD). However, off-target radioligand binding is also observed in basal ganglia, known as an iron-rich region. Hence, it is important to distinguish between radioligand-identified tissue neurodegeneration and iron-related radioligand binding effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!